Eikon Therapeutics, Inc. Common Stock (EIKN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has a cash flow conversion efficiency ratio of -0.139x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-64.96 Million) by net assets ($466.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EIKN stock market capitalisation for the company's overall valuation and market capitalisation.
Eikon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eikon Therapeutics, Inc. Common Stock (EIKN) stock price for real-time trading data and today's change.
Eikon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Review financial agility of Eikon Therapeutics, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
0.041x |
|
Wuhu Fuchun Dye and Weave Co.Ltd.
SHG:605189
|
0.362x |
|
Rieter Holding AG
SW:RIEN
|
-0.126x |
|
Ashiana Housing Limited
NSE:ASHIANA
|
0.116x |
|
KINX Inc
KQ:093320
|
0.056x |
|
ARTS Group Co Ltd
SHG:603017
|
0.042x |
|
Dayang Enterprise Holdings Bhd
KLSE:5141
|
0.048x |
|
Smcp SAS
PA:SMCP
|
0.110x |
Annual Cash Flow Conversion Efficiency for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025. Also see EIKN total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-879.03 Million | $-188.52 Million | 0.214x | -9.01% |
| 2024-12-31 | $-571.93 Million | $-134.80 Million | 0.236x | -57.84% |
| 2023-12-31 | $-341.37 Million | $-190.85 Million | 0.559x | -- |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more